Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Alterations in the gut microbiome and the association of butyrate producers with progression-free survival in multiple myeloma patients undergoing autologous stem cell transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAdolfo AlemanAKAditya Kasina

Discussion

Loading...

Member takes

Overview

Association of gut microbiome and butyrate mediates progression-free survival in multiple myeloma, suggesting microbiome modulation could improve outcomes.

Key Points

  • A significant decrease in butyrate-producing bacteria occurs during stem cell engraftment.
  • Loss of butyrate producers associates with worse progression-free survival in multiple myeloma patients.
  • Analysis utilized 16S rRNA sequencing and a Random Forest predictor to assess gut microbiome impacts.
  • Findings indicate the gut microbiome acts as an actionable biomarker for improving multiple myeloma outcomes.

Cite This Study

Aleman et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d95bhttps://doi.org/10.1182/blood-2025-575
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gut microbiota recovery via butyrate supplementation prevents acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation2025
  2. 2The role of microbial metabolites in fecal microbiota transplantation in patients with acute gvhd of the gut2025
  3. 3Data from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma2025
  4. 4Butyrate enhances gut dysbiosis by activating the cAMP/PKA/CREB signaling pathway to inhibit the progression of endometrial carcinoma2025 · 1 citations
  5. 5Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma2025